News stories about Fortress Biotech (NASDAQ:FBIO) have been trending somewhat positive this week, Accern Sentiment reports. Accern identifies negative and positive media coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Fortress Biotech earned a coverage optimism score of 0.09 on Accern’s scale. Accern also assigned headlines about the biopharmaceutical company an impact score of 46.0561542477298 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.
Here are some of the news headlines that may have impacted Accern Sentiment Analysis’s analysis:
- Checkpoint Therapeutics Receives Orphan Drug Designation for CK-101 for the Treatment of EGFR Mutation-Positive … – Markets Insider (markets.businessinsider.com)
- Checkpoint Therapeutics Receives Orphan Drug Designation For CK-101 For The Treatment Of EGFR Mutation … – Clinical Leader (clinicalleader.com)
- Fortress Biotech, Inc. (FBIO) Downgraded by Zacks Investment Research to Sell (americanbankingnews.com)
- Fortress Biotech, Inc. (FBIO)- Ownership Analysis and Its Impact – Wallstreet Investorplace (wallstreetinvestorplace.com)
- Fortress Biotech, Inc. (FBIO) and Dawson Geophysical Company … – Wallstreet Investorplace (wallstreetinvestorplace.com)
Several equities research analysts recently commented on the stock. Zacks Investment Research lowered shares of Fortress Biotech from a “hold” rating to a “sell” rating in a research note on Tuesday. ValuEngine raised shares of Fortress Biotech from a “sell” rating to a “hold” rating in a research note on Wednesday, June 7th. HC Wainwright set a $11.00 price objective on shares of Fortress Biotech and gave the stock a “buy” rating in a research note on Thursday, August 10th. FBR & Co reissued a “buy” rating on shares of Fortress Biotech in a research note on Tuesday, July 4th. Finally, Rodman & Renshaw assumed coverage on shares of Fortress Biotech in a research note on Tuesday, July 11th. They set a “buy” rating and a $11.00 price objective on the stock. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and five have assigned a buy rating to the company. Fortress Biotech has an average rating of “Buy” and an average price target of $9.67.
Fortress Biotech (FBIO) opened at 4.86 on Wednesday. The firm has a 50-day moving average of $4.43 and a 200 day moving average of $4.05. Fortress Biotech has a one year low of $1.88 and a one year high of $5.13. The stock’s market capitalization is $245.56 million.
COPYRIGHT VIOLATION WARNING: This report was reported by Ticker Report and is the sole property of of Ticker Report. If you are reading this report on another website, it was illegally copied and reposted in violation of US & international trademark and copyright laws. The original version of this report can be accessed at https://www.tickerreport.com/banking-finance/2887782/somewhat-favorable-media-coverage-somewhat-unlikely-to-impact-fortress-biotech-fbio-share-price.html.
About Fortress Biotech
Fortress Biotech, Inc, formerly Coronado Biosciences, Inc, is a biopharmaceutical company. The Company is involved in the development of immunotherapy agents for the treatment of autoimmune diseases and cancer. Its sole product candidate is CNDO-109. The Company is also focused on acquiring, developing and commercializing pharmaceutical and biotechnology products.
Receive News & Ratings for Fortress Biotech Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fortress Biotech Inc. and related companies with MarketBeat.com's FREE daily email newsletter.